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Abstract
Background Combining two standard-of-care medica-
tions for Alzheimer’s disease (AD) into a single once-daily
dosage unit may improve treatment adherence, facilitate
drug administration, and reduce caregiver burden. A new
fixed-dose combination (FDC) capsule containing 28 mg
memantine extended release (ER) and 10 mg donepezil
was evaluated for bioequivalence with co-administered
commercially available memantine ER and donepezil, and
for bioavailability with regard to food intake.
Methods Two phase I, single-dose, randomized, open-
label, crossover studies were conducted in 18- to 45-year-
old healthy individuals. In MDX-PK-104 study, fasting
participants (N = 38) received co-administered memantine
ER and donepezil or the FDC. In MDX-PK-105 study,
participants (N = 36) received three treatments: intact
FDC taken while fasting or after a high-fat meal, or FDC
contents sprinkled on applesauce while fasting. Standard
pharmacokinetic parameters for memantine and donepezil
were calculated from the plasma concentration time-curve
using non-compartmental analyses. Linear mixed-effects
models were used to compare: (a) FDC versus co-admin-
istered individual drugs; (b) FDC fasted versus with food;
and (c) FDC sprinkled on applesauce versus FDC intact,
both fasted. Safety parameters were also evaluated.
Results The FDC capsule was bioequivalent to co-ad-
ministered memantine ER and donepezil. There was no
significant food effect on the bioavailability of the FDC
components. There were no clinically relevant differences
in time to maximum plasma concentration or safety profiles
across treatments.
Conclusions An FDC capsule containing 28 mg me-
mantine ER and 10 mg donepezil is bioequivalent to
commercially available memantine ER and donepezil, and
bioavailability is not affected by food intake or sprinkling
of capsule contents on applesauce.
Key Points
A fixed-dose combination consisting of memantine
extended-release and donepezil is bioequivalent to
the commercially available component drugs.
This can be administered with or without food, the
capsule swallowed intact or with its contents
sprinkled on soft food.
The use of this fixed-dose combination in patients
with moderate to severe Alzheimer’s disease may
facilitate drug administration, improve treatment
adherence, and reduce caregiver burden.
1 Introduction
The most recent best-practice models of care in Alzheimer’s
disease (AD) favor a team-based approach that focuses on
both the patient and the caregiver [1] and includes strategies
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aimed at better medication management and improved ad-
herence [2, 3]. Non-adherence in patients with AD, reported
in up to 42 % of patients [4], is caused by several factors,
including forgetfulness, high caregiver burden, high pill
burden, complex medication regimens, and swallowing
difficulties (dysphagia) [4–7]. Patients with moderate to
severe AD take on average six different medications per day
[4], which frequently includes two anti-dementia agents:
memantine, a non-competitive N-methyl-D-aspartate
(NMDA) receptor antagonist [8], and a cholinesterase in-
hibitor (ChEI: donepezil, galantamine, or rivastigmine) [9].
Memantine is approved for patients in the moderate to
severe stages of the disease in the USA and around the
world, while donepezil, the most frequently prescribed
ChEI, is approved for the entire severity range of AD in the
USA, Canada, Japan, and several other countries (in the
EU, however, it is approved only for mild to moderate
AD). In clinical practice, treatment is usually initiated with
a ChEI (most frequently donepezil) and memantine is
added as the disease progresses. In randomized, placebo-
controlled trials, both drugs were shown to improve cog-
nition, behavior, daily functioning, and global clinical
status [8, 9], and trials using both immediate-release [10]
and extended-release (ER) memantine [11] demonstrated
efficacy and good tolerability in patients already receiving
donepezil. Co-prescribing memantine and donepezil has
been shown to increase medication persistence [12], but co-
administration of these two drugs also increases pill bur-
den. Availability of a once-daily fixed-dose combination
(FDC) consisting of memantine and donepezil, in a for-
mulation that could be sprinkled on soft food (e.g., ap-
plesauce) if needed, could reduce pill burden, simplify
medication management, improve patient safety for those
who have swallowing difficulties, and facilitate caregiving.
We report the results of two phase I clinical trials
(MDX-PK-104 and MDX-PK-105), conducted to deter-
mine: (a) whether a once-daily FDC consisting of 28 mg
memantine ER and 10 mg donepezil is bioequivalent to co-
administered commercially available memantine ER and
donepezil; (b) whether bioavailability of FDC components
is affected by food intake; and (c) whether the intact FDC
capsule is bioequivalent to capsule contents sprinkled on
applesauce. To the best of our knowledge, this represents




Participants in both trials were healthy men and women
between 18 and 45 years of age. Inclusion criteria included
an agreement to use an effective method of contraception
and not become pregnant or have their partners become
pregnant during the study, nonsmoker status (never smoked
or had not smoked within the previous 2 years), body mass
index (BMI) C18 and B30 kg/m2, and sitting pulse
rate C50 and B100 beats/min during vital signs assess-
ments. Exclusion criteria included known hypersensitivity
to memantine, donepezil, or other ChEI or NMDA receptor
antagonists, clinically significant disease state in any body
system or abnormal and clinically significant results at
screening, sitting systolic BP C140 or B90 mmHg, or a
sitting diastolic BP C90 or B50 mmHg at screening, ab-
normal ECG results at screening, a history of alcohol or
substance abuse within the previous 5 years or a positive
test for alcohol or drugs of abuse at screening, consumption
of any grapefruit-containing products within 14 days, caf-
feine within 48 h, or alcohol within 72 h before investi-
gational product administration, taking of any concomitant
medications, including over-the-counter medications,
within 14 days or hormonal drug products within 30 days
before study, or prior exposure to memantine or donepezil,
or previous participation in an investigational study of
memantine or donepezil.
2.2 Study Design
MDX-PK-104 was a phase I, single-center, randomized,
open-label, crossover study. Fasting participants (N = 38)
were randomly assigned to one of two treatment se-
quences (AB or BA) with a 21-day washout period be-
tween treatments. Treatment groups were defined as
Treatment A (co-administered commercially available
memantine HCl ER [Namenda XR 28 mg, Actavis, Inc.,
St Louis, MO, USA] and donepezil HCl [Aricept 10 mg,
Eisai, Inc., Research Triangle Park, NC, USA]) and
Treatment B (FDC consisting of 28 mg memantine ER
and 10 mg donepezil: approved in the USA as
NamzaricTM and manufactured by Actavis, Inc., St Louis,
MO, USA).
MDX-PK-105 was a phase I, single-center, random-
ized, open-label, three-period crossover study in which
participants (N = 36) were randomized to one of six
treatment sequences (ABC, ACB, BAC, BCA, CAB, or
CBA) with a 21-day washout period between each treat-
ment. The 21-day duration of the washout was determined
based on the terminal elimination half-lives of 60–80 h
and 70 h for memantine and donepezil, respectively, and
based on clinical experience to avoid carryover effects.
Treatment A was defined as the intact FDC capsule taken
while fasting, Treatment B as the intact FDC capsule
taken following a high-fat meal, and Treatment C as FDC
capsule contents sprinkled on applesauce and adminis-
tered while fasting.
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2.3 Sample Collection and Analysis
For both studies, blood samples were collected starting on
Day 1 of each treatment period at hour 0 (pre-dose) and at 1,
2, 3, 4, 6, 8, 10, 12, 14, 24, 30, 36, 48, 72, 96, 120, 168, 216,
and 264 h after dosing. Plasma samples were analyzed for
memantine and donepezil concentrations using high-per-
formance liquid chromatography coupled with tandem mass
spectrometry (HPLC MS/MS), with a lower limit of quan-
tification of 0.5 ng/mL for both analytes. Briefly, plasma
samples (100 lL) were combined with 25 lL of internal
standard spiking solution (75/75 ng/mL of [2H6] meman-
tine/[2H7] donepezil in 0.01 N hydrochloric acid) and
200 lL of ammonium hydroxide in 96-well plate wells, and
thoroughly mixed in ThermoMixer (Eppendorf, Germany)
for 5 min. The analytes and their internal standards were
then extracted using methyl tert-butyl ether (MTBE). After
evaporation of the isolated organic layer, the dry residue was
reconstituted in 200 lL of formic acid-water-methanol
acetonitrile solution (2:1200:500:300, by volume). The ad-
dition of MTBE, mixing in support of extraction, MTBE
organic layer transfer, and dry residue reconstitution were all
accomplished using Tomtec liquid handler (Hamden, CT,
USA). A 20-lL aliquot of the final solution was directly
injected into the HPLC-MS/MS system. Chromatographic
separation was achieved using an Agilent Zorbax XDB-C18
column (50 9 4.6 mm; 1.8 lm; Agilent Technologies,
Santa Clara, CA, USA) under isocratic conditions with a
mobile phase of formic acid-water-methanol-acetonitrile
(2:1000:600:400, by volume) and a flow rate of 0.5 mL/min.
Memantine and donepezil were detected using an MDS
Sciex API 3000 mass spectrometer (Applied Biosystems/
Life Technologies, Grand Island, NY, USA). Standard
pharmacokinetic parameters for memantine and donepezil,
calculated from the plasma concentration-time data using
non-compartmental analyses, included area under the plas-
ma concentration-time curve (AUC) from time zero to time
of last quantifiable concentration (AUC0–t; calculated using
the linear trapezoidal rule), AUC from time zero to infinity
(AUC0–?), maximum plasma concentration (Cmax), time to
Cmax (tmax), and terminal elimination half-life (t).
Safety and tolerability evaluations consisted of adverse
event (AE) monitoring, vital signs and clinical laboratory
evaluations (hematology, blood chemistry, urinalysis),
electrocardiogram (ECG) parameters, physical examina-
tions, and results of the Columbia-Suicide Severity Rating
Scale (C-SSRS) [13], a clinician-administered survey on
suicidal ideation and behavior that was assessed at baseline
and on day 4 of each treatment period, and at the end of the
study. AEs were monitored for up to 30 days after the last
dose received. AE severity was assessed by the Principal
Investigator or Sub-Investigator according to the following
scale:
Mild: Minor awareness of signs or symptoms that
are easily tolerated without specific medical
intervention.
Moderate: Discomfort that interferes with usual activities
and may require minimal intervention.
Severe: Significant signs or symptoms that are
incapacitating with an inability to work or
perform routine activities and/or that require
medical intervention.
2.4 Statistical Analyses
In both studies, two populations were considered for sta-
tistical analyses. The pharmacokinetic population included
all participants who completed the study and had evaluable
pharmacokinetic parameters. Individuals who vomited
within 24 h from investigational product administration
were excluded from pharmacokinetic analyses of meman-
tine; those who vomited within twice the median tmax of
donepezil were excluded from the analyses of donepezil.
The safety population included all participants who re-
ceived at least one dose of any treatment. Cmax, AUC0–t,
and AUC0–? for memantine and donepezil were compared
by means of a linear mixed-effects model. Bioequivalence
of memantine and donepezil delivered via different for-
mulations or modes of administration (study MDX-PK-
104: Treatment B vs. A; study MDX-PK-105: Treatment B
vs. A, and Treatment C vs. A) was established if the 90 %
confidence intervals (90 % CIs) for the ratio of geometric
least squares means (GLSM) of Cmax, AUC0–t, and AUC0–?
were contained within the range 0.80–1.25. The differences
in median tmax values were compared using the Wilcoxon
signed-rank test.
3 Results
3.1 Baseline Characteristics and Trial
Discontinuations
Thirty-eight individuals were enrolled in the MDX-PK-104
trial, of which 31 (81.6 %) completed the study. Two
(5.3 %) participants discontinued the trial due to AEs, one
(2.6 %) withdrew consent, one (2.6 %) was lost to follow-
up, and three (7.9 %) discontinued for other reasons. In
MDX-PK-105, out of 36 individuals enrolled, 33 (91.7 %)
completed the study. The three discontinuations were due
to AEs, protocol violation, and other reasons (one [2.8 %]
for each). Demographic characteristics at baseline were
similar between the two trials (Table 1), with the majority
of participants being male, White, and with a mean age
close to 30 years.
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3.2 Study MDX-PK-104
In the trial MDX-PK-104, the number of participants ex-
cluded from the pharmacokinetic analysis of memantine
and donepezil was 15 and 14, respectively. Seven were
excluded due to trial discontinuation (Treatment A, n = 5;
Treatment B, n = 2), eight experienced vomiting within
pre-specified time windows for both memantine and
donepezil (see Sect. 2.4, Methods), of which one also
discontinued the trial, and one experienced vomiting within
the pre-specified time window for memantine only.
The mean plasma concentration-time profiles for both
memantine and donepezil were similar between treatments
(Fig. 1), as were the pharmacokinetic parameters for both
drugs (Table 2). For plasma memantine, median tmax val-
ues were 14 h for Treatment A (co-administration) and
24 h for Treatment B (FDC), but the difference was not
statistically significant (P = 0.27; Table 2). In addition,
the 90 % CI values for GLSM ratios of Cmax, AUC0–t, and
AUC0–? indicate bioequivalence between commercially
available, co-administered drugs and the FDC.
The total treatment-emergent adverse event (TEAE)
rates were similar between treatments (co-administration





Age, years 29.8 ± 7.7a 27.3 ± 5.3a
Women, n (%) 13 (34.2) 11 (30.6)
Men, n (%) 25 (65.8) 25 (69.4)
White, n (%) 22 (57.9) 25 (69.4)
Hispanic, n (%) 12 (31.6) 16 (44.4)
BMI, kg/m2 25.9 ± 3.7a 25.4 ± 2.9a
BMI body mass index
a Mean ± standard deviation
Fig. 1 Study MDX-PK-104: memantine and donepezil concentration
profiles following a single dose of memantine extended release (ER)
plus donepezil (Treatment A) or a fixed-dose combination (FDC)
(Treatment B). a, b Mean memantine plasma concentration-time
profile and c, d mean donepezil plasma concentration-time profile.
Panels on the left a, c represent plasma concentrations ranging from 0
to 264 h; the shaded areas indicate the time windows augmented in
panels b, d on the right (0–48 h)
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77.8 %; FDC 76.5 %), with the most common TEAEs
being nausea, dizziness, vomiting, feeling hot, abdominal
pain, and headache (Table 3). All TEAEs were mild
(80.7 %) or moderate (19.3 %) in severity. A feeling of
body temperature change was reported in 8.3 % of par-
ticipants receiving memantine-donepezil co-administration
(Treatment A) and in none of the participants receiving the
FDC (Treatment B; data not shown), although feeling hot
was reported in 5.6 and 17.7 % of participants, respectively
(Table 3). All other TEAEs were reported in no more than
two individuals per treatment. No deaths or serious adverse
events (SAEs) were reported. Additionally, no clinically
meaningful differences were observed in vital sign, clinical
laboratory, ECG, and physical examination parameters.
The C-SSRS evaluations did not indicate suicidal ideation
or behavior in any of the participants.
3.3 Study MDX-PK-105
In the trial MDX-PK-105, 23 participants were included in
the pharmacokinetic analysis of food effects (intact capsule
administered with or without food) and 21 in the analysis
of intact capsule versus sprinkled contents. Three indi-
viduals were excluded from pharmacokinetic analyses due
to trial discontinuation (one from each treatment). Because
of vomiting (based on both memantine and donepezil cri-
teria: see Sect. 2.4, Methods), ten were excluded from the
Treatment A versus Treatment B comparison and 12 from
the Treatment A versus Treatment C comparison.
The mean plasma concentration-time profiles for both
memantine and donepezil were similar between treatments
(Fig. 2), as were the pharmacokinetic parameters of Cmax,
AUC0–t, and AUC0–? (Table 4). For memantine, median
tmax values associated with Treatment B (intact capsule,
high-fat meal) and Treatment C (capsule contents sprinkled
on applesauce, fasted condition) were both significantly
shorter (14 h for both) than the value observed with
Treatment A (intact capsule, fasted condition; 24 h;










Cmax ng/mL, mean ± SD 28.5 ± 6.3 28.5 ± 6.3 19.3 ± 5.5 19.1 ± 5.3
GLSM ratio (90 % CI) 1.00 (0.97–1.04) 0.99 (0.93–1.04)
AUC0–t ngh/mL, mean ± SD 2782 ± 553 2798 ± 536 748 ± 227 791 ± 230
GLSM ratio (90 % CI) 1.01 (0.98–1.04) 1.06 (1.04–1.08)
AUC0–? ngh/mL, mean ± SD 2966 ± 643 2966 ± 609 838 ± 278 881 ± 269
GLSM ratio (90 % CI) 1.00 (0.97–1.04) 1.06 (1.03–1.08)
tmax h, median (min, max) 14 (12, 36) 24 (12, 36) 3.0 (2.0, 4.1) 3.0 (2.0, 6.0)
Differences in median
(P value)b
10 (0.27) 0 (0.99)
t h, mean ± SD 62 ± 9.3 60 ± 8.8 69 ± 24 69 ± 21
AUC area under the plasma concentration-time curve, AUC0–t AUC from time zero to time of last quantifiable concentration, AUC0–? AUC from
time zero to infinity, Cmax maximum plasma concentration, CI confidence interval, FDC fixed-dose combination, GLSM ratio geometric least
squares mean ratio of Treatments B/A, max maximum, min minimum, SD standard deviation, t terminal elimination half-life, tmax time to Cmax
a Treatment A indicates commercially available memantine extended release (28 mg) and donepezil (10 mg); Treatment B indicates the FDC
b P value calculated using the Wilcoxon signed-rank test
Table 3 Study MDX-PK-104: most common treatment-emergent
adverse events (TEAEs) ([10 % of participants receiving either
treatment; safety population), n (%)
Adverse event Treatment Aa (n = 36) Treatment Ba (n = 34)
Any TEAE 28 (77.8) 26 (76.5)
Nausea 19 (52.8) 22 (64.7)
Dizziness 13 (36.1) 14 (41.2)
Vomiting 7 (19.4) 8 (23.5)
Feeling hot 2 (5.6) 6 (17.7)
Abdominal pain 3 (8.3) 4 (11.8)
Headache 5 (13.9) 4 (11.8)
a Treatment A indicates commercially available memantine ER
(28 mg) and donepezil (10 mg); Treatment B indicates the fixed-dose
combination
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P = 0.014 vs. Treatment B and P = 0.012 vs. Treatment
C; Table 4). For donepezil, Treatment B was associated
with a significantly longer tmax than Treatment A (6 vs. 3 h;
P\ 0.001; Table 4). The 90 % CI values for GLSM ratios
of Cmax, AUC0-t, and AUC0-? indicate bioequivalence
between the intact capsule taken while fasting or after a
high-fat meal, and between the intact capsule and capsule
contents sprinkled on applesauce, both taken while fasting
(Table 4).
The overall TEAE rates ranged from 44.1 % (intact
capsule, high-fat meal) to 67.6 % (capsule contents sprin-
kled on applesauce, fasted), with the most common TEAEs
being nausea, dizziness, vomiting, headache, and ab-
dominal discomfort (Table 5). All reported TEAEs were
mild (74.7 %) or moderate (25.3 %) in severity. There
were no deaths during the study; one SAE (ectopic
pregnancy) was reported, but it was deemed not related to
the investigational product. No clinically meaningful dif-
ferences were observed in vital sign, clinical laboratory,
ECG, and physical examination parameters, and C-SSRS
evaluations did not indicate suicidal ideation or behavior in
any of the participants.
4 Discussion
Results of these two phase I studies indicate that the me-
mantine-donepezil FDC is bioequivalent with commer-
cially available co-administered memantine ER (28 mg)
and donepezil (10 mg), and that administration of the intact
FDC capsule while fasting is bioequivalent with adminis-
tration after a high-fat meal or after capsule contents were
Fig. 2 Study MDX-PK-105: memantine and donepezil concentration
profiles following a single dose of memantine extended release (ER)
plus donepezil fixed-dose combination (FDC) taken while fasting
(Treatment A), after a high-fat meal (Treatment B), or capsule
contents sprinkled on applesauce while fasting (Treatment C). a,
b Mean memantine plasma concentration-time profile and c, d mean
donepezil plasma concentration-time profile. Panels on the left a,
c represent plasma concentrations ranging from 0 to 264 h; the
shaded areas indicate the time windows augmented in panels b, d on
the right (0–48 h)
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sprinkled on applesauce. It should be noted that the sta-
tistically significant differences in tmax values observed in
study MDX-PK-105 (Table 4) were not associated with
significant differences in Cmax.
To the best of our knowledge, this FDC is the first
consisting of two approved anti-dementia medications.
Since memantine and donepezil are frequently co-pre-
scribed in patients with moderate to severe AD, who are
characterized by rapidly declining independence and an
increasing caregiving burden [14], availability of such an
FDC could reduce total pill burden and dosing frequency,
which could potentially improve treatment adherence and
reduce caregiving time and burden. For example, a patient
taking immediate-release memantine and donepezil would
reduce their anti-dementia pill burden from a total of three
pills, administered twice a day, to one capsule once daily.
Data from an observational study conducted in Germany
suggest that switching from orally administered rivastig-
mine to a rivastigmine patch (i.e., to a drug formulation
that reduces pill burden) is associated with improved ad-
herence and with time savings for caregivers of up to
20 min/day [15]. Moreover, data from studies in other
clinical conditions that require multiple medications (e.g.,
diabetes mellitus, cardiovascular disease) suggest that
switching to an FDC is associated with better adherence
[16, 17], clinical improvements [17], and a decrease in
hospitalization risk and healthcare costs [18].
Table 4 Study MDX-PK-105: pharmacokinetic parameters of memantine and donepezil (pharmacokinetic population)
Parameter Memantine Donepezil
Treatment
Aa (n = 23)
Treatment
Ba (n = 23)
Treatment
Ca (n = 21)
Treatment
Aa (n = 23)
Treatment
Ba (n = 23)
Treatment
Ca (n = 21)
Cmax ng/mL, mean ± SD 27.9 ± 5.6 30.0 ± 6.4 30.1 ± 5.4 20.1 ± 3.9 17.3 ± 3.0 20.3 ± 4.4
GLSM ratio (90 % CI) 1.07b,c (0.99–1.15) 1.08d,e (1.01–1.16) 0.86b (0.83–0.90) 0.99c (0.93–1.05)
AUC0–t ngh/mL, mean ± SD 2865 ± 617 2913 ± 671 3113 ± 633 803 ± 190 847 ± 205 803 ± 220
GLSM ratio (90 % CI) 1.01b,c (0.94–1.09) 1.07d,e (0.99–1.15) 1.05b (1.01–1.10) 0.98c (0.94–1.03)
AUC0–? ngh/mL, mean ± SD 3056 ± 736 3096 ± 762 3337 ± 798 875 ± 209 916 ± 219 874 ± 244
GLSM ratio (90 % CI) 1.01b,c (0.94–1.10) 1.09d,e (1.00–1.19) 1.04b (1.00–1.09) 0.98c (0.94–1.03)
tmax h, median (min, max) 24 (12, 36) 14 (12, 30) 14 (12, 36) 3.0 (2.0, 4.1) 6.0 (2.0, 10) 2.1 (2.0, 4.0)
Differences in median
(P value)f
10c (0.014) 10c (0.012) 3e (\0.001) 0.93e (0.278)
t h, mean ± SD 62 ± 13
c 60 ± 12 63 ± 16 67 ± 12 67 ± 10 65 ± 13
AUC area under the plasma concentration-time curve, AUC0–t AUC from time zero to time of last quantifiable concentration, AUC0–? AUC from time
zero to infinity, Cmax maximum plasma concentration, CI confidence interval, FDC fixed-dose combination, GLSM geometric least squares mean, max
maximum, min minimum, SD standard deviation, t terminal elimination half-life, tmax time to Cmax
a Treatment A indicates intact memantine extended release (ER) plus donepezil FDC capsule taken while fasting; Treatment B indicates intact FDC
capsule taken following a high-fat meal; Treatment C indicates FDC capsule contents sprinkled on applesauce and taken while fasting
b Ratio of Treatments B/A
c n = 22
d Ratio of Treatments C/A
e n = 20
f P value calculated using the Wilcoxon signed-rank test
Table 5 Study MDX-PK-105: most common treatment-emergent
adverse events (TEAEs) ([10 % of participants receiving any treat-
ment; safety population), n (%)






Any TEAE 22 (62.9) 15 (44.1) 23 (67.6)
Nausea 20 (57.1) 12 (35.3) 19 (55.9)
Dizziness 15 (42.9) 4 (11.8) 9 (26.5)
Vomiting 10 (28.6) 2 (5.9) 8 (23.5)
Headache 4 (11.4) 3 (8.8) 6 (17.6)
Abdominal
discomfort
3 (8.6) 2 (5.9) 2 (5.9)
FDC fixed-dose combination
a Treatment A indicates intact memantine extended release (ER) plus
donepezil FDC capsule taken while fasting; Treatment B indicates
intact FDC capsule taken following a high-fat meal; Treatment C
indicates FDC capsule contents sprinkled on applesauce and taken
while fasting
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The ability to open the FDC capsule and sprinkle the
contents on soft food (e.g., applesauce) may facilitate
caregiving for patients who have swallowing difficulties [5,
19, 20], including choking [21], a condition that affects up
to 57 % of patients with dementia [22] and constitutes a
major challenge in nursing homes [23]. In addition, chal-
lenges with swallowing may be exacerbated by feeding
tubes [25] and lead to aspiration pneumonia [26], a com-
mon cause of morbidity and death in patients with AD [27].
Currently, caregivers of patients with dysphagia rely on
either liquid drug formulations or crushed pills mixed with
soft foods [28], but the latter practice may be incompatible
with many drug formulations (especially enteric-coated or
extended-release ones) [28], leading to efficacy or safety
issues, and may even amount to unlicensed drug use and be
associated with legal ramifications [29]. Capsule
manufacturers are aware of these issues and easy-to-open
products are already available on the market [24].
Our data indicate that the memantine ER/donepezil FDC
is generally safe in healthy individuals, and randomized-trial
data suggest that the observed tolerability issues (par-
ticularly gastrointestinal, likely stemming from a known
ChEI effect [9]) would be transient and less prominent in
clinical practice, in which doses of both component drugs
would be gradually up- titrated (recommended up-titration
for donepezil: 4–6 weeks [30]; recommended up-titration
for memantine ER: 4 weeks [31]). Similar to other phase I
studies of anti-dementia medications, data have been ob-
tained from healthy individuals who were on average
40 years younger than a typical patient, who would also be
expected to have several co-morbidities. Therefore, phar-
macokinetic parameters reported here are not necessarily
representative of the parameters that would be observed in a
population of patients with AD.
5 Conclusion
In conclusion, the memantine ER plus donepezil FDC cap-
sule provides an additional treatment option for patients with
moderate to severe AD and their caregivers. Introduction of
a once-daily memantine ER/donepezil FDC which can be
sprinkled may facilitate caregiving for patients with mod-
erate to severe AD and potentially improve clinical out-
comes, through increased treatment adherence. Our studies
indicate that the FDC capsule containing memantine ER and
donepezil is bioequivalent to co-administered commercially
available memantine ER and donepezil, can be taken with or
without food, and that its contents can be sprinkled on ap-
plesauce to facilitate drug intake.
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